Clinical trial
A Single-Arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Putelimab and Vibostolimab as Second-Line Therapy in Patients With Advanced Anal Squamous Cell Carcinoma
NCT07934745 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Putelimab and Vibostolimab as Second-Line Therapy in Patients With Advanced Anal Squamous Cell Carcinoma
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2028
- Enrollment
- 33 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
anal cancer
Arms
As registered; 1 arm.
-
treatment
Radiotherapy is delivered to recurrent or metastatic lesions. Thereafter, the PD-1 inhibitor putelimab in combination with the EGFR-targeted ADC vibostolimab is administered once every 3 weeks until disease progression or intolerable toxicity.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Objective Response Rate (ORR)
the proportion of participants achieving a Complete Response (CR) or Partial Response (PR) among all enrolled participants.
Lead sponsor's other trials
Fudan University, most recent start first.
+1,311 more trials See the organization page
Similar trials
Same condition (Anus Neoplasms) and phase, most recent start first.
+57 more trials See the condition page